Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis [0.03%]
前列腺特异抗原最低值对转移性雄激素敏感型前列腺癌预后的影响：系统评价及个体患者数据的meta-分析
Mattia Alberto Di Civita,Laura Pappalardo,Danila De Angelis et al.
Mattia Alberto Di Civita et al.
Background: Prostate cancer represents the third leading cause of cancer-related mortality in the male population. Androgen deprivation therapy efficacy has been significantly enhanced by the addition of docetaxel chemoth...
CDK4/6 Inhibitors in Breast Cancer Therapy: Mechanisms, Resistance, and Emerging Opportunities [0.03%]
乳腺癌治疗中的CDK4/6抑制剂：机制、耐药性和新兴机遇
Luis Chinea,Caroline Hauer,Khushboo Pal et al.
Luis Chinea et al.
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have significantly changed the treatment approach for hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative (HER2-) breast cancer in both metastatic and...
P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast [0.03%]
P-VERIFY：在美国HR阳性/HER2阴性转移性乳腺癌患者中，CDK4/6抑制剂联合芳香化酶抑制剂的现实世界总生存期和无进展生存期比较——一期播客视频节目
Hope S Rugo,Joanne C Ryan
Hope S Rugo
To date, there have been no head-to-head randomized controlled trial data comparing cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in patients with HR+/HER2- metastatic breast cancer (mBC), and most prior real-world comparative effectivene...
Subcutaneous Amivantamab and Lazertinib in PALOMA-3: Efficacy, Safety, and Administration: A Vodcast [0.03%]
PALOMA-3中的潜行给药阿米万塔马布和拉泽廷尼布：疗效、安全性和给药方式：视频播客
Danny Nguyen
Danny Nguyen
Intravenous (IV) amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, is approved for multiple indications alone or in combination for patients with EGFR-mutated advanced or metastatic nonsmall cell lung cancer (...
FGF/FGFR Alteration Type as a Candidate Enrichment Biomarker for Gunagratinib in Recurrent or Metastatic Head and Neck Cancer: An Exploratory Analysis of Two Early-Phase Trials [0.03%]
两项一期临床试验中作为复发或转移性头颈部鳞癌的Gunagratinib潜在生物标志物的FGF/FGFR基因异常类型的一项探索性分析
Liqiong Xue,Guopei Zhu,Peiguo Wang et al.
Liqiong Xue et al.
Background: FGF/FGFR alterations are recurrent but heterogeneous in head and neck cancer, and which types predict benefit from selective fibroblast growth factor receptor (FGFR) inhibition is unknown. ...
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study) [0.03%]
基于序贯疗法的基线疾病特征和铂类药物敏感性对晚期尿路上皮癌患者预后的预测价值：Atezo-2EV研究
Mimma Rizzo,Sebastiano Buti,Ondřej Fiala et al.
Mimma Rizzo et al.
Background: Numerous case series have corroborated the efficacy of the first-line approach of platinum-based chemotherapy and avelumab maintenance followed by enfortumab vedotin monotherapy (PBC-AM-EV) in real-world patie...
Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years [0.03%]
肝细胞癌治疗格局变化的实证研究：10年回顾性分析治疗算法及患者预后情况
Melanie Bathon,Nele Binder,Sabrina Welland et al.
Melanie Bathon et al.
Background: Hepatocellular carcinoma is one of the most common cancers worldwide and the third leading cause of cancer-related mortality. The therapeutic landscape of hepatocellular carcinoma, especially systemic therapie...
Hendrik Schürmann,Wungki Park,Grainne M O&#x;Kane et al.
Hendrik Schürmann et al.
For the past decades, chemotherapy constituted the therapeutic foundation in advanced or metastatic pancreatic cancer. Despite significant advances in the molecular understanding, translation into tangible patient benefit has remained modes...
From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board [0.03%]
从推荐到实施：单一中心分子肿瘤委员会的临床结果
Tabea Fröhlich,Ulrich Lehmann,Tanja Reineke-Plaaß et al.
Tabea Fröhlich et al.
Background: Molecular tumor boards (MTBs) support precision oncology by translating genomic profiling into evidence-based treatment recommendations, for example according to the European Society for Medical Oncology Scale...
Matthew S Block,Ashley E Stenzel,Rene Marcotte et al.
Matthew S Block et al.
Background: Melanoma has an excellent prognosis when detected at a localized stage, but when patients present with regional or distant metastases, 5-year survival decreases to approximately 76% and 35%, respectively. Alth...